Triphase in-licenses clinically enabled oncology assets with high-value potential and develops them in a shared risk model to proof of concept (POC), then out-licenses or sells the product to realize value. Triphase has a strategic partnership with Bristol-Myers Squibb to enable the rapid development of proof of concept in important new cancer therapeutics of mutual interest. The Triphase management team is deeply knowledgeable with significant experience in drug development. Together with the founding organizations Ontario Institute for Cancer Research (OICR) and Toronto Innovation Acceleration Partners (TIAP, formerly MaRS Innovation), and supported by MaRS Discovery District along with other academic and corporate partners, Triphase has formed a unique partnership to produce proof-of-concept data for investors, partners, regulators, payers, and ultimately prescribers and patients.
Our Mission is to accelerate the development of promising cancer therapies from pre-IND to proof of concept (Phase II) in order to bring more effective, affordable treatments to cancer patients, faster than traditional drug development.
Triphase focuses on accelerating oncology products from pre-investigational new drug (pre-IND) to Phase I/Phase II POC in less time with less capital than traditional pharma and biotech approaches. It accomplishes this through support from world-class scientists, clinicians, and business professionals, state-of-the-art facilities and entrepreneurial resources predominantly in Canada and the United States.
Triphase draws on the people, skills and infrastructure represented in the Toronto / Ontario and San Diego / Southern California bio hubs, and taps into expertise around the world.
Triphase is differentiated from other Biotechs:
Strategic relationship with Bristol-Myers Squibb, one of the top cancer biopharmaceutical companies in the world.
Lean semi-virtual operating model, providing a low risk, low cost, fast approach to accelerating novel compounds to proof of concept.
Strategic relationship with OICR, one of the world’s leading oncology translational research institutes, enabling
investor access to biomarkers, tumor bank, genomics technology, and informatics capabilities.
Strategic relationship with Toronto Innovation Acceleration Partners (TIAP, formerly MaRS Innovation), providing access to world-leading research at its member institutions, which include many of Toronto’s top universities, institutions and research institutes.
Experience and access to a global clinical trial footprint, including the U.S., Canada, Europe, and Australia, which
provide many strategic, operational, and financial advantages.